These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23742976)

  • 41. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of breast cancer resistance protein on cancer treatment outcomes.
    Ross DD; Nakanishi T
    Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
    Storch CH; Ehehalt R; Haefeli WE; Weiss J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
    Gupta A; Unadkat JD; Mao Q
    J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2).
    Mahringer A; Delzer J; Fricker G
    Eur J Pharm Biopharm; 2009 Aug; 72(3):605-13. PubMed ID: 19572416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: Botany, traditional uses, phytochemistry, pharmacokinetic and toxicity studies.
    Zhang H; Wang X; Guo Y; Liu X; Zhao X; Teka T; Lv C; Han L; Huang Y; Pan G
    J Ethnopharmacol; 2021 Mar; 268():113566. PubMed ID: 33166629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Separation, identification and rapid determination of liensine, isoliensinine and neferine from embryo of the seed of Nelumbo nucifera Gaertn. by liquid chromatography coupled to diode array detector and tandem mass spectrometry.
    Chen Y; Fan G; Wu H; Wu Y; Mitchell A
    J Pharm Biomed Anal; 2007 Jan; 43(1):99-104. PubMed ID: 16846715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
    Kovalev AA; Tsvetaeva DA; Grudinskaja TV
    Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
    Wright JA; Haslam IS; Coleman T; Simmons NL
    Eur J Pharmacol; 2011 Dec; 672(1-3):70-6. PubMed ID: 22004608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
    Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.